card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

A new ELISpot/FluoroSpot best practice using a novel lyophilized FBS for clinical immune monitoring assays

Home / Insights / A new ELISpot/FluoroSpot best practice using a novel lyophilized FBS for clinical immune monitoring assays

Interferon gamma (IFN) ELISpot and FluoroSpot are widely used immune monitoring assays to detect functional cell responses in clinical studies.  Recognized for their importance in vaccine development studies to quantitate immune responses, these assays have more recently risen to the forefront in cell and gene therapy as well as cancer immunotherapy fields where responses against cancer neoantigens are not easily detectable above assay background. Here, we test a new class of fetal bovine serum (FBS), CultraPure FBS, in ex vivo ELISpot and FluoroSpot assays and in a cultured Fluorospot assay following in vitro expansion. Several CultraPure FBS lots that have been specially formulated through the process of lyophilization (lyo-FBS) were compared to liquid CultraPure FBS. We stimulated human PBMCs with peptide pools diluted in media supplemented with either liquid CultraPure FBS or lyo-FBS. Equivalent cytokine production with negligible to no assay background were observed from all lots and FBS formats. Moreover, all lots and FBS formats showed lot-to-lot consistency and 90-day refrigerated (4oC) stability in both ex-vivo direct and in-vitro cultured assays.  In addition, we present here a FluoroSpot method using lyo-FBS supplemented media, cytokines, and peptide pools which supports the expansion of low frequency antigen-specific T cells, mimicking the low frequency seen with cancer neoantigens. Our results demonstrate the presence of Granzyme B, Interferon gamma (IFN ), and Tumor Necrosis Factor (TNF) production by antigen-specific polyfunctional T cells following a 9-day culture using media supplemented with lyo-FBS. These results represent a new best practice and demonstrate the performance characteristics of a new lyophilized format of FBS which should improve the resolution of signal from noise in ELISpot and FluoroSpot immune monitoring in Clinical studies.

 

Complete the form to access this scientific poster